BGI Genomics Co

BGI Genomics Co Receivables

The Accounts Receivable of BGI Genomics Co (300676.SZ) as of Nov 3, 2026 is 1.67 B CNY. In the previous year, Accounts Receivable was 1.44 B CNY — a change of 15.36% (higher).

Receivables

1.67 BCNY

YoY

15.36%

Last updated:

Accounts Receivable of BGI Genomics Co is 2024 1.67 B CNY. Accounts Receivable of BGI Genomics Co was 2023 1.44 B CNY. It decreases by 15.36% higher compared to the previous year.

The BGI Genomics Co Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2017
812.00 M CNY
Jan 1, 2018
1.25 B CNY
Jan 1, 2019
1.23 B CNY
Jan 1, 2020
1.56 B CNY
Jan 1, 2021
1.21 B CNY
Jan 1, 2022
2.21 B CNY
Jan 1, 2023
1.44 B CNY
Jan 1, 2024
1.67 B CNY
The BGI Genomics Co Receivables history
YEARReceivablesYoY
1.67 BCNY+15.36%
1.44 BCNY-34.75%
2.21 BCNY+82.16%
1.21 BCNY-22.12%
1.56 BCNY+26.62%
1.23 BCNY-1.44%
1.25 BCNY+53.94%
812.00 MCNY+32.68%
612.00 MCNY+26.19%
485.00 MCNY+47.42%
329.00 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BGI Genomics Co Stock analysis

What does BGI Genomics Co do? BGI Genomics Co., Ltd. generates revenue through its core services in genomics, including reproductive health basic research and clinical application services, basic science research services such as genome sequencing and bioinformatics analysis, complex disease research and clinical applications, and drug-related research services. The company primarily serves academic institutions, research institutes, independent laboratories, pharmaceutical companies, hospitals, and medical institutions both domestically and internationally. Its domestic market focus allows it to cater to a wide range of clients seeking advanced genomic solutions for research and healthcare applications. The firm's revenue streams are derived from providing specialized genomic services to institutions and companies involved in medical research and healthcare. By offering multithreaded solutions in genome sequencing and bioinformatics, BGI Genomics supports clients in advancing their scientific and clinical objectives. The company's domestic market operations enable it to maintain strong relationships with key stakeholders in China's healthcare and research sectors. BGI Genomics' service portfolio includes reproductive health, complex disease, and drug development research, all of which are critical areas for pharmaceutical and medical institutions. These services are tailored to meet the needs of academic and commercial clients, driving demand for its genomic analysis and research support. The company's focus on domestic operations ensures alignment with local healthcare and research priorities. BGI Genomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BGI Genomics Co stock

Accounts Receivable of BGI Genomics Co is 1.67 B CNY in 2024.

Accounts Receivable of BGI Genomics Co changed from 1.44 B CNY to 1.67 B CNY, representing a 15.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable BGI Genomics Co since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's BGI Genomics Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BGI Genomics Co

All Key Metrics — BGI Genomics Co